{"id":781900,"date":"2023-09-05T17:37:51","date_gmt":"2023-09-05T21:37:51","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/phaxiam-therapeutics-publishes-its-cash-position-and-new-financial-calendar-and-announces-its-participation-at-upcoming-investor-conferences\/"},"modified":"2023-09-05T17:37:51","modified_gmt":"2023-09-05T21:37:51","slug":"phaxiam-therapeutics-publishes-its-cash-position-and-new-financial-calendar-and-announces-its-participation-at-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/phaxiam-therapeutics-publishes-its-cash-position-and-new-financial-calendar-and-announces-its-participation-at-upcoming-investor-conferences\/","title":{"rendered":"PHAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <strong>P<\/strong><br \/>\n        <strong>HAXIAM<\/strong><br \/>\n        <strong> Therapeutics <\/strong><br \/>\n        <strong>publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Lyon (France) and Cambridge (MA, US)<\/strong><br \/>\n        <strong>, <\/strong><br \/>\n        <strong>September<\/strong><br \/>\n        <strong>5<\/strong><br \/>\n        <strong>, <\/strong><br \/>\n        <strong>2023<\/strong><br \/>\n        <strong>\u2013<\/strong><br \/>\n        <strong>10:05 p.m. CEST &#8211; <\/strong><br \/>\n        <strong>P<\/strong><br \/>\n        <strong>HAXIAM<\/strong><br \/>\n        <strong> Therapeutics (Nasdaq &amp; Euronext: <\/strong><br \/>\n        <strong>PHXM<\/strong><br \/>\n        <strong>) <\/strong><br \/>\n        <strong>(the &#8220;Company&#8221;)<\/strong><br \/>\n        <strong>,<\/strong><br \/>\n        <strong>today publishes its cash position a<\/strong><br \/>\n        <strong>s of<\/strong><br \/>\n        <strong> June 30, 2023<\/strong><br \/>\n        <strong>,<\/strong><br \/>\n        <strong> and its financial calendar for the second half of 2023<\/strong><br \/>\n        <strong>.<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <u>Cash position a<\/u><br \/>\n        <\/strong><br \/>\n        <strong><br \/>\n          <u>s of<\/u><br \/>\n        <\/strong><br \/>\n        <strong><br \/>\n          <u> June 30, 2023<\/u><br \/>\n        <\/strong>\n      <\/p>\n<p align=\"justify\">As of June 30, 2023, PHAXIAM Therapeutics had cash and cash equivalents totaling \u20ac25.2 million (approximately $27.5 million).<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <u>New financial publication dates for the second half of 2023<\/u><br \/>\n        <\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <strong>Update on business and key financial data for 2<\/strong><br \/>\n          <sup><br \/>\n            <strong><br \/>\n              <em>nd<\/em><br \/>\n            <\/strong><br \/>\n          <\/sup><br \/>\n          <strong> quarter and 1<\/strong><br \/>\n          <sup><br \/>\n            <strong><br \/>\n              <em>st<\/em><br \/>\n            <\/strong><br \/>\n          <\/sup><br \/>\n          <strong> half 2023<\/strong>: September 21, 2023 (after US market close), followed by a conference call and webcast on September 25, 2023 (2:30 pm CET\/8:30 am ET). <\/p>\n<\/li>\n<li style=\"text-align:justify\">\n          <strong>Update on business and key financial data for Q3 2023:<\/strong> November 14, 2023 (after US market close), followed by a conference call and webcast on November 15, 2023 (2:30 pm CET\/8:30 am ET).<\/p>\n<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong><br \/>\n          <u>Upcoming investor conferences<\/u><br \/>\n        <\/strong>\n      <\/p>\n<p align=\"justify\">To meet the Company&#8217;s management at one of the conferences below, please contact the organizer or PHAXIAM Therapeutics directly (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AOHhp0kamqbm8EKiHSKkfBG4uItyDXA27KIJfc-PbdUclX4-A-NGkrA4uMvFGPYe2qoxZvR4Bhu5NdUlclIiEsUNoXZrI1UQlmXWI1iZRDM=\" rel=\"nofollow noopener\" target=\"_blank\">investors@phaxiam.com<\/a>).<\/p>\n<p>\n        <strong>H.C. Wainwright BioConnect <\/strong>\n      <\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MtkqDmGTLhdKCJHCA7nZZ67TGu-IZU9WQHArBEz3wc2FidMJFoxPyLEKGrr3EXt0t7SVIVd2ZYJcnvn03GQxgTMV-EAoFZIXq1bd1F7t8ws=\" rel=\"nofollow noopener\" target=\"_blank\">Event link<\/a>\n      <\/p>\n<ul type=\"disc\">\n<li>Dates: Monday, September 11 &#8211; Thursday September 14, 2023<\/li>\n<li>Place: New York<\/li>\n<li>Participants: Thibaut du Fayet (CEO), Eric Soyer (COO &amp; CFO), Pascal Birman (CMO)\n<\/li>\n<\/ul>\n<p>\n        <strong>Portzamparc BPN Paribas Biotech<\/strong><br \/>\n        <strong> &amp;<\/strong><br \/>\n        <strong> Health Seminar<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>Dates: Wednesday, October 4 &#8211; Thursday, October 5, 2023<\/li>\n<li>Digital format with a presentation on Tuesday October 5 from 2:30 to 3:15 pm<\/li>\n<li>Participants: Thibaut du Fayet, Eric Soyer\n<\/li>\n<\/ul>\n<p>\n        <strong>Investor Access Event<\/strong>\n      <\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MtkqDmGTLhdKCJHCA7nZZ4EDhEwnf8eMDH8p-HScuJtl1gkttVth_8B0-1b2ifbql6J5am9zUMd61WbRI8qTOHgiFJz77ER7fa6rLf9eOvg=\" rel=\"nofollow noopener\" target=\"_blank\">Event link<\/a>\n      <\/p>\n<ul type=\"disc\">\n<li>Dates: Monday, October 9 &#8211; Tuesday, October 10, 2023<\/li>\n<li>Place: Paris<\/li>\n<li>Participants: Thibaut du Fayet, Eric Soyer\n<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>About PHAXIAM<\/strong><br \/>\n        <strong>Therapeutics<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <em>PHAXIAM<\/em><br \/>\n        <em>is<\/em><br \/>\n        <em>a<\/em><br \/>\n        <em>biopharmaceutical<\/em><br \/>\n        <em>company<\/em><br \/>\n        <em>developing<\/em><br \/>\n        <em>innovative<\/em><br \/>\n        <em>treatments<\/em><br \/>\n        <em>for<\/em><br \/>\n        <em>resistant<\/em><br \/>\n        <em>bacterial<\/em><br \/>\n        <em>infections,<\/em><br \/>\n        <em>which are responsible for many serious infections. The company is building on an innovative approach based on the<\/em><br \/>\n        <em>use of<\/em><br \/>\n        <em>phages,<\/em><br \/>\n        <em>natural<\/em><br \/>\n        <em>bacterial-killing<\/em><br \/>\n        <em>viruses.<\/em><br \/>\n        <em>PHAXIAM<\/em><br \/>\n        <em>is<\/em><br \/>\n        <em>developing<\/em><br \/>\n        <em>a<\/em><br \/>\n        <em>portfolio<\/em><br \/>\n        <em>of<\/em><br \/>\n        <em>phages<\/em><br \/>\n        <em>targeting<\/em><br \/>\n        <em>3<\/em><br \/>\n        <em>of<\/em><br \/>\n        <em>the<\/em><br \/>\n        <em>most resistant<\/em><br \/>\n        <em>and<\/em><br \/>\n        <em>dangerous<\/em><br \/>\n        <em>bacteria,<\/em><br \/>\n        <em>which<\/em><br \/>\n        <em>together<\/em><br \/>\n        <em>account<\/em><br \/>\n        <em>for<\/em><br \/>\n        <em>more<\/em><br \/>\n        <em>than<\/em><br \/>\n        <em>two-thirds<\/em><br \/>\n        <em>of<\/em><br \/>\n        <em>resistant<\/em><br \/>\n        <em>hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas<\/em><br \/>\n        <em>aeruginosa.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <em>PHAXIAM<\/em><br \/>\n        <em>is<\/em><br \/>\n        <em>listed<\/em><br \/>\n        <em>on<\/em><br \/>\n        <em>the<\/em><br \/>\n        <em>Nasdaq<\/em><br \/>\n        <em>Capital<\/em><br \/>\n        <em>Market<\/em><br \/>\n        <em>in<\/em><br \/>\n        <em>the<\/em><br \/>\n        <em>United<\/em><br \/>\n        <em>States<\/em><br \/>\n        <em>(ticker:<\/em><br \/>\n        <em>PHXM)<\/em><br \/>\n        <em>and<\/em><br \/>\n        <em>on<\/em><br \/>\n        <em>the<\/em><br \/>\n        <em>Euronext<\/em><br \/>\n        <em>regulated market<\/em><br \/>\n        <em>in<\/em><br \/>\n        <em>Paris<\/em><br \/>\n        <em>(ISIN<\/em><br \/>\n        <em>code:<\/em><br \/>\n        <em>FR0011471135,<\/em><br \/>\n        <em>ticker:<\/em><br \/>\n        <em>PHXM).<\/em><br \/>\n        <em>PHAXIAM<\/em><br \/>\n        <em>is<\/em><br \/>\n        <em>part<\/em><br \/>\n        <em>of<\/em><br \/>\n        <em>the<\/em><br \/>\n        <em>CAC<\/em><br \/>\n        <em>Healthcare,<\/em><br \/>\n        <em>CAC<\/em><br \/>\n        <em>Pharma<\/em><br \/>\n        <br \/>\n        <em>&amp; Bio, CAC Mid &amp; Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech<\/em><br \/>\n        <em>indexes. For more information, please visit<\/em><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=itsnj5kC9g9QUccvf6RMWJqxXPSePQ8EjBKZ5dRYtnM18h-nhb92cGoVcLChC1e-LaiMga8xTXjn8D45zrFQfYrSe5Sc0DTL7HnEDcIcun0=\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n          <em><br \/>\n            <u>www.erytech.com<\/u><br \/>\n          <\/em><br \/>\n        <\/a>\n      <\/p>\n<p>\n        <strong>Contacts<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;margin-left:5.3pt;width:481.95pt;border-collapse:collapse\">\n<tr>\n<td style=\"width:262.27px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">\n            <strong>PHAXIAM<\/strong><br \/>\n            <br \/>\n            <strong>Eric Soyer<\/strong><br \/>\n            <br \/>COO &amp; CFO<br \/>+33 4 78 74 44 38<br \/><a href=\"mailto:investors@erytech.com\" rel=\"nofollow noopener\" target=\"_blank\">investors@phaxiam.com<\/a><\/td>\n<td style=\"width:380.34px;vertical-align: middle;text-align: left;padding-left: 30.0px;vertical-align: top\">\n            <strong>NewCap<\/strong><br \/>\n            <br \/>\n            <strong>Mathilde Bohin \/ Louis-Victor<\/strong><br \/>\n            <strong>Delouvrier<\/strong><br \/>\n            <br \/>Investor Relations<br \/><strong>Arthur<\/strong><strong>Rouill\u00e9 <\/strong><br \/>Media Relations <br \/>+33 1 44 71 94 94<br \/><a href=\"mailto:phaxiam@newcap.eu\" rel=\"nofollow noopener\" target=\"_blank\"><u>phaxiam@newcap.eu<\/u><\/a><\/td>\n<\/tr>\n<\/table>\n<p \/>\n<p id=\"gnw_attachments_section-header\">\n        <strong>Attachment<\/strong>\n      <\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n          <a target=\"_blank\" href=\"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/30822a0b-be3a-4d3e-9bd7-804924b8e2ca\" rel=\"noopener\">PR_PHAXIAM_05092023_Financial calendar_EN_vf<\/a>\n        <\/li>\n<\/ul>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgzODExNSM0MDE2MDUxMTYjMjAyMDIzMg==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/MzBiNGUxMGQtNmJhZS00MTRmLWFhNzEtYWEzNTMyNTI2YzBhLTEwMzE4MDQ=\/tiny\/Phaxiam-Therapeutics-S-A-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>P HAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences Lyon (France) and Cambridge (MA, US) , September 5 , 2023 \u2013 10:05 p.m. CEST &#8211; P HAXIAM Therapeutics (Nasdaq &amp; Euronext: PHXM ) (the &#8220;Company&#8221;) , today publishes its cash position a s of June 30, 2023 , and its financial calendar for the second half of 2023 . Cash position a s of June 30, 2023 As of June 30, 2023, PHAXIAM Therapeutics had cash and cash equivalents totaling \u20ac25.2 million (approximately $27.5 million). New financial publication dates for the second half of 2023 Update on business and key financial data for 2 nd quarter and 1 st half &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/phaxiam-therapeutics-publishes-its-cash-position-and-new-financial-calendar-and-announces-its-participation-at-upcoming-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;PHAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-781900","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>PHAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/phaxiam-therapeutics-publishes-its-cash-position-and-new-financial-calendar-and-announces-its-participation-at-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PHAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"P HAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences Lyon (France) and Cambridge (MA, US) , September 5 , 2023 \u2013 10:05 p.m. CEST &#8211; P HAXIAM Therapeutics (Nasdaq &amp; Euronext: PHXM ) (the &#8220;Company&#8221;) , today publishes its cash position a s of June 30, 2023 , and its financial calendar for the second half of 2023 . Cash position a s of June 30, 2023 As of June 30, 2023, PHAXIAM Therapeutics had cash and cash equivalents totaling \u20ac25.2 million (approximately $27.5 million). New financial publication dates for the second half of 2023 Update on business and key financial data for 2 nd quarter and 1 st half &hellip; Continue reading &quot;PHAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/phaxiam-therapeutics-publishes-its-cash-position-and-new-financial-calendar-and-announces-its-participation-at-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-05T21:37:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgzODExNSM0MDE2MDUxMTYjMjAyMDIzMg==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/phaxiam-therapeutics-publishes-its-cash-position-and-new-financial-calendar-and-announces-its-participation-at-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/phaxiam-therapeutics-publishes-its-cash-position-and-new-financial-calendar-and-announces-its-participation-at-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"PHAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences\",\"datePublished\":\"2023-09-05T21:37:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/phaxiam-therapeutics-publishes-its-cash-position-and-new-financial-calendar-and-announces-its-participation-at-upcoming-investor-conferences\\\/\"},\"wordCount\":426,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/phaxiam-therapeutics-publishes-its-cash-position-and-new-financial-calendar-and-announces-its-participation-at-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDgzODExNSM0MDE2MDUxMTYjMjAyMDIzMg==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/phaxiam-therapeutics-publishes-its-cash-position-and-new-financial-calendar-and-announces-its-participation-at-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/phaxiam-therapeutics-publishes-its-cash-position-and-new-financial-calendar-and-announces-its-participation-at-upcoming-investor-conferences\\\/\",\"name\":\"PHAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/phaxiam-therapeutics-publishes-its-cash-position-and-new-financial-calendar-and-announces-its-participation-at-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/phaxiam-therapeutics-publishes-its-cash-position-and-new-financial-calendar-and-announces-its-participation-at-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDgzODExNSM0MDE2MDUxMTYjMjAyMDIzMg==\",\"datePublished\":\"2023-09-05T21:37:51+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/phaxiam-therapeutics-publishes-its-cash-position-and-new-financial-calendar-and-announces-its-participation-at-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/phaxiam-therapeutics-publishes-its-cash-position-and-new-financial-calendar-and-announces-its-participation-at-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/phaxiam-therapeutics-publishes-its-cash-position-and-new-financial-calendar-and-announces-its-participation-at-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDgzODExNSM0MDE2MDUxMTYjMjAyMDIzMg==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDgzODExNSM0MDE2MDUxMTYjMjAyMDIzMg==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/phaxiam-therapeutics-publishes-its-cash-position-and-new-financial-calendar-and-announces-its-participation-at-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PHAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PHAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/phaxiam-therapeutics-publishes-its-cash-position-and-new-financial-calendar-and-announces-its-participation-at-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"PHAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences - Market Newsdesk","og_description":"P HAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences Lyon (France) and Cambridge (MA, US) , September 5 , 2023 \u2013 10:05 p.m. CEST &#8211; P HAXIAM Therapeutics (Nasdaq &amp; Euronext: PHXM ) (the &#8220;Company&#8221;) , today publishes its cash position a s of June 30, 2023 , and its financial calendar for the second half of 2023 . Cash position a s of June 30, 2023 As of June 30, 2023, PHAXIAM Therapeutics had cash and cash equivalents totaling \u20ac25.2 million (approximately $27.5 million). New financial publication dates for the second half of 2023 Update on business and key financial data for 2 nd quarter and 1 st half &hellip; Continue reading \"PHAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/phaxiam-therapeutics-publishes-its-cash-position-and-new-financial-calendar-and-announces-its-participation-at-upcoming-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-05T21:37:51+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgzODExNSM0MDE2MDUxMTYjMjAyMDIzMg==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/phaxiam-therapeutics-publishes-its-cash-position-and-new-financial-calendar-and-announces-its-participation-at-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/phaxiam-therapeutics-publishes-its-cash-position-and-new-financial-calendar-and-announces-its-participation-at-upcoming-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"PHAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences","datePublished":"2023-09-05T21:37:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/phaxiam-therapeutics-publishes-its-cash-position-and-new-financial-calendar-and-announces-its-participation-at-upcoming-investor-conferences\/"},"wordCount":426,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/phaxiam-therapeutics-publishes-its-cash-position-and-new-financial-calendar-and-announces-its-participation-at-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgzODExNSM0MDE2MDUxMTYjMjAyMDIzMg==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/phaxiam-therapeutics-publishes-its-cash-position-and-new-financial-calendar-and-announces-its-participation-at-upcoming-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/phaxiam-therapeutics-publishes-its-cash-position-and-new-financial-calendar-and-announces-its-participation-at-upcoming-investor-conferences\/","name":"PHAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/phaxiam-therapeutics-publishes-its-cash-position-and-new-financial-calendar-and-announces-its-participation-at-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/phaxiam-therapeutics-publishes-its-cash-position-and-new-financial-calendar-and-announces-its-participation-at-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgzODExNSM0MDE2MDUxMTYjMjAyMDIzMg==","datePublished":"2023-09-05T21:37:51+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/phaxiam-therapeutics-publishes-its-cash-position-and-new-financial-calendar-and-announces-its-participation-at-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/phaxiam-therapeutics-publishes-its-cash-position-and-new-financial-calendar-and-announces-its-participation-at-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/phaxiam-therapeutics-publishes-its-cash-position-and-new-financial-calendar-and-announces-its-participation-at-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgzODExNSM0MDE2MDUxMTYjMjAyMDIzMg==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgzODExNSM0MDE2MDUxMTYjMjAyMDIzMg=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/phaxiam-therapeutics-publishes-its-cash-position-and-new-financial-calendar-and-announces-its-participation-at-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"PHAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/781900","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=781900"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/781900\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=781900"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=781900"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=781900"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}